Edison Investment Research - IRLAB Therapeutics (IRLAB A) IRLAB Therapeutics - Pirepemat passes Phase IIb DSMB safety hurdle

Report

Edison Investment Research

Sean Conroy

IRLAB Therapeutics - Pirepemat passes Phase IIb DSMB safety hurdle

IRLAB Therapeutics has successfully completed the second and final of two pre-determined safety and data integrity reviews for its ongoing Phase IIb clinical trial (React PD) for pirepemat. The study will assess the ability to improve balance and reduce falls in patients with Parkinson’s disease (PD-Falls). The independent data and safety monitoring board (DSMB) has unanimously recommended that the React PD study should continue without any changes. Hence, and in line with previous guidance, patient recruitment remains on track to be completed in Q324, and we expect top-line results to be shared in Q424 or Q125, which would be after the three-month treatment period, follow-up visits and required data analyses.

03/07/2024 1 EN

Underlying

IRLAB Therapeutics

IRLAB Therapeutics AB is a Sweden-based research and development company. It focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinson's disease. The Company possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The Company operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinson's Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).

See profile

SE0012675361 Nasdaq Nordic Stockholm Sweden

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Sean Conroy

Other Reports on these Companies

ABG Sundal Collier Sponsored

IRL757 brings new flavour

IRLAB has made important progress with its pipeline in the last six months. The lead programme mesdopetam passed the FDA end-of-Ph 2 meeting, paving the way for a pivotal Ph 3.

June 25, 2024 June 25, 2024 1 EN

Edison Investment Research

IRLAB Therapeutics - Mesdopetam disease-modifying potential

Researchers in China studying IRLAB’s lead asset, mesdopetam (IRL790) in a preclinical model for levodopa-induced dyskinesia in Parkinson’s disease (PD-LIDs) have noted that the treatment not only improved dyskinesia in the tested rodents but also potentially demonstrated neuroprotective (disease-modifying) properties by restoring or improving alterations in dendritic spine density in the implicated regions. We view the latter as a key observation, given that PD continues to be a progressive disease currently addressed with only symptomatic treatments. However, this data would need to be repro...

June 17, 2024 June 17, 2024 1 EN

Helios Underwriting - Delivery into a strong underwriting cycle

Helios Underwriting (Helios) delivered strong EPS of 21.6p in FY23, from a loss of 3.1p in FY22, ahead of our 14.7p forecast. On 7 June, the company announced that CEO Martin Reith had stepped down, with Michael Wade taking over as executive chair. Mr Reith had driven a strategy of investment in internal capabilities and Lloyd’s of London (Lloyd’s) capacity expansion via tenancy capacity and promotor activities. While Helios will still pursue select capacity acquisition, indications are that future strategy will increasingly be focused on extracting value from the existing portfolio, with grea...

11h / 37m 11h / 37m 1 EN

Sean Conroy

Sean Conroy

Creo Medical - Intuitive deal expansion is a notable milestone

Creo Medical has expanded its collaborative agreement with leading robotics manufacturer Intuitive Surgical, to include additional sites in the UK and Europe testing MicroBlate Flex in combination with Intuitive’s Ion surgical system for combined lung cancer diagnostics and treatment. The first such successful procedure under a clinical trial setting was announced in March 2024 by Professor Shah at Royal Brompton Hospital and the addition of new centres could potentially drive accelerated adoption of the MicroBlate Flex (commercial roll-out is planned over the next 12 months, with first proced...

19h / 33m 19h / 33m 1 EN

Richard Williamson

Richard Williamson

Nano Dimension - Agreement to acquire Desktop Metal

Nano Dimension has entered into a definitive agreement to acquire Desktop Metal (DM) in an all-cash deal worth $185m ($5.50 per DM share), with potential adjustments that could reduce it to $135m ($4.07 per share). The deal is subject to regulatory approvals and DM shareholder approval and is expected to close in Q424. With complementary product lines, the combined entity will offer a broad range of additive manufacturing solutions covering multiple verticals and materials, supporting the entire value chain from prototyping through to mass manufacturing.

19h / 46m 19h / 46m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

IRLAB Therapeutics - Pirepemat passes Phase IIb DSMB safety hurdle

IRL757 brings new flavour

IRLAB Therapeutics - Mesdopetam disease-modifying potential

Helios Underwriting - Delivery into a strong underwriting cycle

Creo Medical - Intuitive deal expansion is a notable milestone

Nano Dimension - Agreement to acquire Desktop Metal

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe